4.5 Review

Prophylactic Erythropoietin for Neuroprotection in Very Preterm Infants: A Meta-Analysis Update

Related references

Note: Only part of the references are listed.
Article Pediatrics

Transfusions and neurodevelopmental outcomes in extremely low gestation neonates enrolled in the PENUT Trial: a randomized clinical trial

Phuong T. Vu et al.

Summary: Transfusions in ELGANs were associated with worse outcomes. Strategies to minimize the need for transfusions may improve neurodevelopmental outcomes, with factors such as transfusion number, volume, and donor exposure playing a significant role in affecting neurodevelopment.

PEDIATRIC RESEARCH (2021)

Article Medicine, General & Internal

A Randomized Trial of Erythropoietin for Neuroprotection in Preterm Infants

Sandra E. Juul et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Letter Medicine, General & Internal

Neurodevelopmental Outcomes at Age 5 Years After Prophylactic Early High-Dose Recombinant Human Erythropoietin for Neuroprotection in Very Preterm Infants

Giancarlo Natalucci et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Article Obstetrics & Gynecology

Randomized trial of early erythropoietin supplementation after preterm birth: Iron metabolism and outcome

O. M. Peltoniemi et al.

EARLY HUMAN DEVELOPMENT (2017)

Article Clinical Neurology

Recombinant Human Erythropoietin Improves Neurological Outcomes in Very Preterm Infants

Juan Song et al.

ANNALS OF NEUROLOGY (2016)

Article Pediatrics

Using the Bayley-III to assess neurodevelopmental delay: which cut-off should be used?

Samantha Johnson et al.

PEDIATRIC RESEARCH (2014)

Article Clinical Neurology

Erythropoietin Improves Neurodevelopmental Outcome of Extremely Preterm Infants

Achim-Peter Neubauer et al.

ANNALS OF NEUROLOGY (2010)